Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: erin4 who wrote (13566)	1/21/1998 8:36:00 AM
From: Henry Niman	Respond to of 32384

erin, I thought that 1997 would be LGND's big year. They did set a 52-week of 18 3/8, but came back down due to selling on the news, a weak biotech sector, and market concerns over Asia. The stock has "flown" several times, but this is the year I expect it to stay up there. LGND has been steady progress as expected. Their base is huge (technolgy, alliances, and clinical trials) and product launches, coupled with FDA reform and the big boys' desire to find those "blockbuster drugs", will speed progress and profitability. I consider LGND's price to be extremely attractive at this time.

To: erin4 who wrote (13566)	1/21/1998 9:03:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

erin, CNBC just mentioned a CNTO upgrade (target price is $44) and suggested that such a move may help move high tech money into Biotechs.